Hospital
Aspirus Ironwood Hospital & Clinics, INC.
Aspirus Ironwood Hospital & Clinics, INC. was paid $9.31M by Medicaid between Jan 2018 and Dec 2024, across 179 billing codes. Its largest line is 99284, emergency room visit (serious) — 21% of everything it billed.
33Billing provider infoASPIRUS IRONWOOD HOSPITAL & CLINICS, INC.
IRONWOOD, MI 49938
IRONWOOD, MI 49938
33aNPI1649297342assigned 07/17/2006
33bProvider typeCritical Access Hospital
28Total paid$9.31M
24GClaims326,175
24DCodes billed179
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Michigan
Rank by total paid#7 of 31
Median peer was paid$6.03M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official YANG, JERRY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 52,316 | $1.12M | |
| 2019 | 48,571 | $971K | |
| 2020 | 35,233 | $1.01M | |
| 2021 | 46,326 | $1.43M | |
| 2022 | 50,358 | $1.60M | |
| 2023 | 49,887 | $1.59M | |
| 2024incomplete | 43,484 | $1.59M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 13,832 | 9,439 | $1.94M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 18,683 | 12,279 | $1.68M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.9% | 3,515 | 2,887 | $827K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.6% | 8,214 | 6,120 | $615K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.5% | 4,172 | 3,661 | $423K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.4% | 3,428 | 1,846 | $409K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 3.3% | 2,990 | 2,815 | $306K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.5% | 8,198 | 3,080 | $229K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 3,524 | 1,878 | $225K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.2% | 3,019 | 2,836 | $201K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 1,918 | 1,350 | $198K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.9% | 3,361 | 2,933 | $181K |
167 more codes
| 71046 | Radiologic examination, chest; 2 views | 1.6% | 6,365 | $148K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 3,302 | $110K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,214 | $87K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,870 | $86K |
| 80053 | Comprehensive metabolic panel | <1% | 20,774 | $85K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,302 | $78K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,831 | $74K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,908 | $72K |
| 73564 | <1% | 2,633 | $60K | |
| 80061 | Lipid panel | <1% | 5,528 | $60K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 20,515 | $59K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,544 | $56K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,816 | $51K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,028 | $49K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,029 | $49K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 440 | $46K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,048 | $44K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 145 | $37K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,996 | $35K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 347 | $33K |
| 36415 | Collection of venous blood by venipuncture | <1% | 22,903 | $32K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 335 | $32K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,218 | $31K |
| 73030 | <1% | 2,026 | $31K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,859 | $31K |
| 73630 | <1% | 2,218 | $30K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,250 | $25K |
| 97162 | <1% | 392 | $25K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,483 | $24K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,461 | $21K |
| 80306 | <1% | 3,253 | $19K | |
| 87070 | <1% | 4,368 | $19K | |
| 82607 | <1% | 2,011 | $19K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,893 | $17K |
| 73110 | <1% | 1,061 | $16K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 356 | $16K |
| 73610 | <1% | 1,350 | $16K | |
| 86900 | <1% | 358 | $14K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 807 | $14K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 173 | $14K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 565 | $13K |
| 73130 | <1% | 1,029 | $13K | |
| 85027 | <1% | 3,359 | $13K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,349 | $12K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 677 | $11K |
| 97161 | <1% | 218 | $11K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,321 | $10K |
| 81001 | <1% | 8,844 | $10K | |
| 83735 | <1% | 4,813 | $10K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,451 | $10K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 124 | $10K |
| 82728 | <1% | 1,203 | $10K | |
| 84439 | <1% | 1,591 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,192 | $9K |
| 82746 | <1% | 820 | $8K | |
| 85610 | <1% | 4,215 | $7K | |
| 83880 | <1% | 800 | $7K | |
| 84484 | <1% | 3,569 | $6K | |
| 83550 | <1% | 1,099 | $6K | |
| 76642 | <1% | 134 | $5K | |
| 87088 | <1% | 1,210 | $5K | |
| 81514 | <1% | 27 | $5K | |
| 86140 | <1% | 3,013 | $5K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 242 | $5K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 134 | $5K |
| 80074 | <1% | 157 | $5K | |
| 83540 | <1% | 1,160 | $4K | |
| 83690 | <1% | 2,896 | $4K | |
| 83605 | <1% | 2,373 | $4K | |
| 87077 | <1% | 1,123 | $4K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 158 | $4K |
| 73502 | <1% | 281 | $4K | |
| 84702 | <1% | 385 | $3K | |
| 86803 | <1% | 348 | $3K | |
| 82043 | <1% | 801 | $3K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 26 | $3K |
| 87186 | <1% | 775 | $3K | |
| 81025 | <1% | 2,071 | $3K | |
| 82150 | <1% | 1,844 | $3K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 119 | $3K |
| 87806 | <1% | 164 | $3K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 41 | $3K |
| 85730 | <1% | 1,945 | $2K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 138 | $2K |
| 76830 | Ultrasound, transvaginal | <1% | 66 | $2K |
| 85651 | <1% | 1,075 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 718 | $2K |
| 85379 | <1% | 1,127 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 52 | $2K |
| 82550 | <1% | 1,114 | $2K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 24 | $2K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 27 | $2K |
| 74018 | <1% | 206 | $2K | |
| 87040 | <1% | 875 | $1K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 54 | $1K |
| 74019 | <1% | 268 | $1K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 24 | $1K |
| 86592 | <1% | 402 | $1K | |
| 72110 | <1% | 71 | $1K | |
| 86769 | <1% | 36 | $1K | |
| 84481 | <1% | 102 | $1K | |
| 97035 | <1% | 147 | $981.65 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 26 | $940.84 |
| 94762 | <1% | 98 | $631.35 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 52 | $590.62 |
| 96367 | <1% | 14 | $575.42 | |
| 87634 | <1% | 12 | $527.90 | |
| 80305 | <1% | 46 | $439.91 | |
| 84145 | <1% | 92 | $418.38 | |
| 82553 | <1% | 391 | $400.50 | |
| 72100 | <1% | 22 | $370.23 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,959 | $346.40 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 26 | $340.03 |
| 82948 | <1% | 405 | $339.01 | |
| 87210 | <1% | 100 | $334.19 | |
| 82570 | <1% | 93 | $322.50 | |
| 73140 | <1% | 21 | $313.87 | |
| 84703 | <1% | 195 | $301.30 | |
| 86850 | <1% | 342 | $257.12 | |
| 87340 | <1% | 34 | $231.22 | |
| 87480 | <1% | 17 | $213.62 | |
| 87510 | <1% | 17 | $212.33 | |
| 87660 | <1% | 17 | $211.69 | |
| Q3014 | Telehealth originating site facility fee | <1% | 28 | $183.54 |
| 84153 | <1% | 15 | $155.71 | |
| 73080 | <1% | 22 | $142.33 | |
| 92015 | Determination of refractive state | <1% | 108 | $133.79 |
| 82962 | <1% | 445 | $133.00 | |
| 86039 | <1% | 25 | $130.24 | |
| 87807 | <1% | 25 | $126.37 | |
| 87205 | <1% | 70 | $120.10 | |
| 86762 | <1% | 12 | $118.86 | |
| 80076 | <1% | 16 | $106.99 | |
| 86901 | <1% | 358 | $106.74 | |
| 85007 | <1% | 87 | $102.15 | |
| 85652 | <1% | 44 | $70.10 | |
| 96376 | <1% | 275 | $49.82 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,806 | $43.74 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,313 | $24.91 |
| A9270 | Non-covered item or service | <1% | 49 | $22.02 |
| 36416 | <1% | 409 | $18.74 | |
| 90715 | <1% | 14 | $17.44 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 20 | $16.40 |
| 85018 | <1% | 12 | $15.54 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,343 | $15.24 |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 23 | $12.88 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,268 | $11.60 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 994 | $6.17 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 364 | $5.75 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 64 | $5.41 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 892 | $4.48 |
| 81003 | <1% | 13 | $1.78 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 477 | $0.07 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 671 | $0.01 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 149 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 210 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 69 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 294 | $0.00 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 47 | $0.00 |
| 36000 | 0% | 54 | $0.00 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 66 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 48 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 96 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 284 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 44 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 70 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 47 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYANG, JERRY (SVP & CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.